Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016, provides an overview of the Pseudomonas aeruginosa Infections (Infectious Disease) pipeline landscape.
Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers and headache. Risk factors include age and weakened immune system.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pseudomonas aeruginosa Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pseudomonas aeruginosa Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 4, 3, 52, 22 and 2 respectively. Similarly, the Universities portfolio in Preclinical, Discovery and Unknown stages comprises 11, 12 and 1 molecules, respectively.Pseudomonas aeruginosa Infections.
Pseudomonas aeruginosa Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pseudomonas aeruginosa Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Pseudomonas aeruginosa Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Pseudomonas aeruginosa Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Pseudomonas aeruginosa Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Pseudomonas aeruginosa Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Achaogen Inc
Adenium Biotech ApS
Aeolus Pharmaceuticals Inc
AlgiPharma AS
AmpliPhi Biosciences Corp
AnGes MG Inc
Arch Biopartners, Inc.
Aridis Pharmaceuticals LLC
Arno Therapeutics Inc
AstraZeneca Plc
Biolytics Pharma
Catabasis Pharmaceuticals Inc
Cellceutix Corp
CSA Biotechnologies LLC
Cyclacel Pharmaceuticals Inc
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd
FOB Synthesis Inc
GlaxoSmithKline Plc
Helix BioMedix Inc
Hsiri Therapeutics LLC
Immun System IMS AB
Insmed Inc
Lascco SA
Laurent Pharmaceuticals Inc
LegoChem Biosciences Inc
Lytix Biopharma AS
MedImmune LLC
Melinta Therapeutics Inc
Microbiotix Inc
Nosopharm SAS
Novabiotics Ltd
Omnia Molecular Ltd
Peptilogics Inc
Pfizer Inc
Pherecydes Pharma SA
Phico Therapeutics Ltd
Polyphor Ltd
Procarta Biosystems Ltd
Sanofi
Sarepta Therapeutics Inc
Sealife PHARMA GMBH
Sequoia Sciences Inc
Shionogi & Co Ltd
Soligenix Inc
Syntiron LLC
Tetraphase Pharmaceuticals Inc
Varinel Inc
Vaxdyn SL
Zambon Company SpA
'
Table of Contents
Table of Contents 2
Introduction 5
Pseudomonas aeruginosa Infections Overview 6
Therapeutics Development 7
Pseudomonas aeruginosa Infections - Therapeutics under Development by Companies 9
Pseudomonas aeruginosa Infections - Therapeutics under Investigation by Universities/Institutes 13
Pseudomonas aeruginosa Infections - Pipeline Products Glance 15
Pseudomonas aeruginosa Infections - Products under Development by Companies 19
Pseudomonas aeruginosa Infections - Products under Investigation by Universities/Institutes 24
Pseudomonas aeruginosa Infections - Companies Involved in Therapeutics Development 26
Pseudomonas aeruginosa Infections - Therapeutics Assessment 76
Drug Profiles 88
Pseudomonas aeruginosa Infections - Dormant Projects 220
Pseudomonas aeruginosa Infections - Discontinued Products 225
Pseudomonas aeruginosa Infections - Product Development Milestones 226
Appendix 237
List of Tables
Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19
Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Development by Companies, H2 2016 (Contd..1) 22
Number of Products under Development by Companies, H2 2016 (Contd..2) 23
Number of Products under Development by Companies, H2 2016 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H2 2016 26
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Development, H2 2016 29
Comparative Analysis by Unknown Stage Development, H2 2016 30
Products under Development by Companies, H2 2016 31
Products under Development by Companies, H2 2016 (Contd..1) 32
Products under Development by Companies, H2 2016 (Contd..2) 33
Products under Development by Companies, H2 2016 (Contd..3) 34
Products under Development by Companies, H2 2016 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2016 36
Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 37
Pseudomonas aeruginosa Infections - Pipeline by Achaogen Inc, H2 2016 38
Pseudomonas aeruginosa Infections - Pipeline by Adenium Biotech ApS, H2 2016 39
Pseudomonas aeruginosa Infections - Pipeline by Aeolus Pharmaceuticals Inc, H2 2016 40
Pseudomonas aeruginosa Infections - Pipeline by AlgiPharma AS, H2 2016 41
Pseudomonas aeruginosa Infections - Pipeline by AmpliPhi Biosciences Corp, H2 2016 42
Pseudomonas aeruginosa Infections - Pipeline by AnGes MG Inc, H2 2016 43
Pseudomonas aeruginosa Infections - Pipeline by Arch Biopartners, Inc., H2 2016 44
Pseudomonas aeruginosa Infections - Pipeline by Aridis Pharmaceuticals LLC, H2 2016 45
Pseudomonas aeruginosa Infections - Pipeline by Arno Therapeutics Inc, H2 2016 46
Pseudomonas aeruginosa Infections - Pipeline by AstraZeneca Plc, H2 2016 47
Pseudomonas aeruginosa Infections - Pipeline by Biolytics Pharma, H2 2016 48
Pseudomonas aeruginosa Infections - Pipeline by Catabasis Pharmaceuticals Inc, H2 2016 49
Pseudomonas aeruginosa Infections - Pipeline by Cellceutix Corp, H2 2016 50
Pseudomonas aeruginosa Infections - Pipeline by CSA Biotechnologies LLC, H2 2016 51
Pseudomonas aeruginosa Infections - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 52
Pseudomonas aeruginosa Infections - Pipeline by Evaxion Biotech ApS, H2 2016 53
Pseudomonas aeruginosa Infections - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 54
Pseudomonas aeruginosa Infections - Pipeline by FOB Synthesis Inc, H2 2016 55
Pseudomonas aeruginosa Infections - Pipeline by GlaxoSmithKline Plc, H2 2016 56
Pseudomonas aeruginosa Infections - Pipeline by Helix BioMedix Inc, H2 2016 57
Pseudomonas aeruginosa Infections - Pipeline by Hsiri Therapeutics LLC, H2 2016 58
Pseudomonas aeruginosa Infections - Pipeline by Immun System IMS AB, H2 2016 59
Pseudomonas aeruginosa Infections - Pipeline by Insmed Inc, H2 2016 60
Pseudomonas aeruginosa Infections - Pipeline by Lascco SA, H2 2016 61
Pseudomonas aeruginosa Infections - Pipeline by Laurent Pharmaceuticals Inc, H2 2016 62
Pseudomonas aeruginosa Infections - Pipeline by LegoChem Biosciences Inc, H2 2016 63
Pseudomonas aeruginosa Infections - Pipeline by Lytix Biopharma AS, H2 2016 64
Pseudomonas aeruginosa Infections - Pipeline by MedImmune LLC, H2 2016 65
Pseudomonas aeruginosa Infections - Pipeline by Melinta Therapeutics Inc, H2 2016 66
Pseudomonas aeruginosa Infections - Pipeline by Microbiotix Inc, H2 2016 67
Pseudomonas aeruginosa Infections - Pipeline by Nosopharm SAS, H2 2016 68
Pseudomonas aeruginosa Infections - Pipeline by Novabiotics Ltd, H2 2016 69
Pseudomonas aeruginosa Infections - Pipeline by Omnia Molecular Ltd, H2 2016 70
Pseudomonas aeruginosa Infections - Pipeline by Peptilogics Inc, H2 2016 71
Pseudomonas aeruginosa Infections - Pipeline by Pfizer Inc, H2 2016 72
Pseudomonas aeruginosa Infections - Pipeline by Pherecydes Pharma SA, H2 2016 73
Pseudomonas aeruginosa Infections - Pipeline by Phico Therapeutics Ltd, H2 2016 74
Pseudomonas aeruginosa Infections - Pipeline by Polyphor Ltd, H2 2016 75
Pseudomonas aeruginosa Infections - Pipeline by Procarta Biosystems Ltd, H2 2016 76
Pseudomonas aeruginosa Infections - Pipeline by Sanofi, H2 2016 77
Pseudomonas aeruginosa Infections - Pipeline by Sarepta Therapeutics Inc, H2 2016 78
Pseudomonas aeruginosa Infections - Pipeline by Sealife PHARMA GMBH, H2 2016 79
Pseudomonas aeruginosa Infections - Pipeline by Sequoia Sciences Inc, H2 2016 80
Pseudomonas aeruginosa Infections - Pipeline by Shionogi & Co Ltd, H2 2016 81
Pseudomonas aeruginosa Infections - Pipeline by Soligenix Inc, H2 2016 82
Pseudomonas aeruginosa Infections - Pipeline by Syntiron LLC, H2 2016 83
Pseudomonas aeruginosa Infections - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 84
Pseudomonas aeruginosa Infections - Pipeline by Varinel Inc, H2 2016 85
Pseudomonas aeruginosa Infections - Pipeline by Vaxdyn SL, H2 2016 86
Pseudomonas aeruginosa Infections - Pipeline by Zambon Company SpA, H2 2016 87
Assessment by Monotherapy Products, H2 2016 88
Assessment by Combination Products, H2 2016 89
Number of Products by Stage and Target, H2 2016 91
Number of Products by Stage and Mechanism of Action, H2 2016 94
Number of Products by Stage and Route of Administration, H2 2016 97
Number of Products by Stage and Molecule Type, H2 2016 99
Pseudomonas aeruginosa Infections - Dormant Projects, H2 2016 232
Pseudomonas aeruginosa Infections - Dormant Projects (Contd..1), H2 2016 233
Pseudomonas aeruginosa Infections - Dormant Projects (Contd..2), H2 2016 234
Pseudomonas aeruginosa Infections - Dormant Projects (Contd..3), H2 2016 235
Pseudomonas aeruginosa Infections - Dormant Projects (Contd..4), H2 2016 236
Pseudomonas aeruginosa Infections - Discontinued Products, H2 2016 237
List of Figures
Number of Products under Development for Pseudomonas aeruginosa Infections, H2 2016 19
Number of Products under Development for Pseudomonas aeruginosa Infections - Comparative Analysis, H2 2016 20
Number of Products under Development by Companies, H2 2016 21
Number of Products under Investigation by Universities/Institutes, H2 2016 25
Comparative Analysis by Late Stage Development, H2 2016 27
Comparative Analysis by Clinical Stage Development, H2 2016 28
Comparative Analysis by Early Stage Products, H2 2016 29
Comparative Analysis by Unknown Stage Development, H2 2016 30
Assessment by Monotherapy Products, H2 2016 88
Assessment by Combination Products, H2 2016 89
Number of Products by Top 10 Targets, H2 2016 90
Number of Products by Stage and Top 10 Targets, H2 2016 90
Number of Products by Top 10 Mechanism of Actions, H2 2016 93
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 93
Number of Products by Routes of Administration, H2 2016 96
Number of Products by Stage and Routes of Administration, H2 2016 96
Number of Products by Top 10 Molecule Types, H2 2016 98
Number of Products by Stage and Top 10 Molecule Types, H2 2016 98
